Registry of patients with AQP4+ NMOSD treated with C5 inhibitors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational registry collects long-term data on patients diagnosed with AQP4+ NMOSD who are being treated with Alexion's C5 inhibitor therapies. It aims to gather information on clinical outcomes, safety, and patient-reported outcomes over a period of approximately five years. Participants will provide retrospective medical histories and treatment details, allowing researchers to assess the real-world impact of these therapies on quality of life and disease management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participant is ≥ 18 years of age at the time of enrollment in the Registry.
* Participant must have a confirmed diagnosis of AQP4+ NMOSD.
* At the time of enrollment in the Registry, participants must be receiving treatment with ALXN-C5IT for the purpose of chronic relapse prevention in a manner consistent with the local label. Specifically, they should have received at least 1 dose of eculizumab within 4 weeks prior to enrollment or at least 1 dose of ravulizumab within 12 weeks prior to enrollment.
* Participants must have both the following historical data available to be enrolled in the Registry: ALXN-C5IT dosing information since initiation and number and types of relapses from 1 year prior to ALXN-C5IT initiation through Registry enrollment.

Exclusion Criteria:

* Participants currently enrolled in an interventional clinical study for the treatment of AQP4+ NMOSD in which the intervention is a drug.

Where it's running

• Clinical Trial Site
  Washington D.C., District of Columbia, United States Recruiting
• Research Site
  Boston, Massachusetts, United States Recruiting
• Clinical Trial Site
  Columbus, Ohio, United States Recruiting
• Clinical Trial Site
  Plano, Texas, United States Recruiting
• Clinical Trial Site
  Milwaukee, Wisconsin, United States Recruiting
• Clinical Trial Site
  Buenos Aires, Argentina Recruiting

Study contacts

• Principal investigator: Pablo Lopez — Hospital Aleman
• Study coordinator: Alexion Pharmaceuticals, Inc. (Sponsor)
• Email: clinicaltrials@alexion.com
• Phone: 1-855-752-2356

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ravulizumab in Chinese adults with NMOSD

  This study tests ravulizumab in Chinese adults with NMOSD who are AQP4 antibody positive to see if it helps reduce relapses and is safe.

  Recruiting Phase 3 Alexion Pharmaceuticals, Inc. · Beijing and 9 other locations · NCT07557420

• Evaluating satralizumab for children with neuromyelitis optica spectrum disorder

  This study is testing a new treatment called satralizumab to see if it helps children aged 2 to 11 with neuromyelitis optica spectrum disorder feel better and stay safe.

  Recruiting at 13 sites Phase 3 Hoffmann-La Roche · Denver, Colorado and 13 other locations · NCT05199688

• Transcranial alternating current stimulation for cognitive problems in inflammatory demyelinating CNS disorders

  This trial will try transcranial alternating current stimulation to see if it improves thinking and memory in adults with multiple sclerosis and related inflammatory demyelinating central nervous system disorders.

  Recruiting Xuanwu Hospital, Beijing · Beijing, Beijing Municipality · NCT07087873

• Rituximab vs multiple approved NMOSD therapies to prevent relapses

  This study tests whether rituximab or one of four other approved medicines is better at preventing NMOSD relapses in adults who have AQP4-IgG.

  Recruiting at 2 sites Phase 4 Massachusetts General Hospital · Boston, Massachusetts and 2 other locations · NCT07010302

• Pregnancy registry for women with chronic neurological conditions

  This study is collecting information and samples from pregnant women with chronic neurological conditions to see how pregnancy affects their health and their baby's development.

  Recruiting University of California, San Francisco · San Francisco, California · NCT06940323

• Targeted CAR-T therapy for autoimmune diseases

  This study is testing a new CAR-T cell therapy to see if it can help people with autoimmune diseases like lupus, scleroderma, and multiple sclerosis feel better.

  Recruiting Early Phase 1 Nanjing Bioheng Biotech Co., Ltd. · Lianyungang, Jiangus · NCT06775912

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.